<DOC>
	<DOCNO>NCT00394953</DOCNO>
	<brief_summary>This 2 arm study compare efficacy safety Mircera darbepoetin alfa , administer extend dosing interval , maintenance treatment anemia patient chronic kidney disease ( CKD ) hemodialysis . Eligible patient receive once-weekly intravenous ( IV ) darbepoetin alfa maintenance treatment randomize receive either intravenous Mircera month ( start dose 120 , 200 360 micrograms/month , depend weekly dose darbepoetin alfa prior start study ) intravenous darbepoetin alfa every 2 week switch monthly administration . The anticipated time study treatment 3-12 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study Mircera Maintenance Treatment Anemia Dialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; chronic renal anemia ; hemodialysis 3 time weekly &gt; =12 week screen , screening/baseline period ; receive darbepoetin alfa maintenance therapy &gt; =8 week screen , screening/baseline period . overt gastrointestinal bleeding within 8 week screen screening/baseline period ; transfusion red blood cell within 8 week screen screening/baseline period ; active malignancy ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>